Prescient Therapeutics Ltd (PTX) News

Prescient Therapeutics Names Chief Medical Officer, Shares Jump 9%

MT NewswiresJun 11 10:53

Prescient Tightens Governance With Updated Securities Trading Policy

TipRanksFeb 25 08:03

Prescient Widens Half-year Loss as R&D Spend Climbs but Bolsters Balance Sheet

TipRanksFeb 24 14:17

Prescient Therapeutics Ltd: Appendix 4D and Half Year Financial Report

ASXFeb 24 14:00 · Announcements

Zenocutuzumab Treatment Beyond Progression Demonstrates Continued Benefit in Patients With NRG1+ Non-Small Cell Lung Cancer: New Results From the ENRGy Trial

PR NewswireFeb 20 21:00

Green Canada Upsizes Financing as PTX Loses Control Ahead of MAACKK Reverse Takeover

TipRanksFeb 5 22:38

Prescient Therapeutics Issues 21.78m Unquoted Options Under Employee Incentive Plan

TipRanksDec 19, 2025 11:38

Prescient Therapeutics Secures European Authorization to Start Clinical Trial in Italy; Shares Hit Two-Year High

MT NewswiresDec 15, 2025 11:06

Mycosis Fungoides Market Set to Expand by 2034 With Advancements in Targeted and Immunotherapy Approaches | DelveInsight

PR NewswireNov 27, 2025 06:31

Prescient Therapeutics Announces Director's Acquisition of Options

TipRanksNov 21, 2025 08:28

Prescient Secures EMA Orphan Drug Designation for PTX-100 in CTCL | ASX:PTX, OTC:PSTTF

Proactive InvestorsNov 19, 2025 06:37

Prescient Therapeutics Issues New Employee Incentive Options

TipRanksNov 18, 2025 09:28

Prescient Therapeutics Amends Constitution to Support Strategic Goals

TipRanksOct 28, 2025 13:18

Prescient Therapeutics Announces Hybrid Annual General Meeting

TipRanksSep 12, 2025 10:07

Prescient Therapeutics Completes $3 Million Share Placement to Advance Cancer Therapies

TipRanksAug 29, 2025 14:25

Prescient Therapeutics Lists New Securities on ASX

TipRanksAug 29, 2025 14:25

Prescient Therapeutics Reports Financial Results With Focus on R&D Investment

TipRanksAug 20, 2025 14:47

Prescient Therapeutics Ltd: Appendix 4E and 2025 Annual Report

ASXAug 20, 2025 14:29 · Announcements

Prescient Raises A$6.8M Through Share Purchase Plan, Launches Placement Offer | ASX:PTX, OTC:PSTTF

Proactive InvestorsJul 29, 2025 09:02

Prescient Therapeutics Eyes 'Inflection Point', US$1.8 Billion Market With Cancer Drug PTX-100 | ASX:PTX, OTC:PSTTF

Proactive InvestorsJul 24, 2025 10:22